tbuckley/cabot-search huggingface dataset:
Controllable‐Swelling Microneedle–Assisted Ultrasensitive Paper Sensing Platforms for Personal Health Monitoring
Authors: Yi‐Chia Hsieh, Chih‐Yu Lin, Hsin‐Yao Lin, Chun‐Ting Kuo, Shin‐Yi Yin, Ying‐Hua Hsu, Hsiu‐Feng Yeh, Jane Wang, Dehui Wan
Journal: Advanced Healthcare Materials (2023)

Microneedle (MN) patches, which allow the extraction of skin interstitial fluid (ISF) without a pain sensation, are powerful tools for minimally invasive biofluid sampling. Herein, an MN-assisted paper-based sensing platform that enables rapid and painless biofluid analysis with ultrasensitive molecular recognition capacity is developed. First, a controllable-swelling MN patch is constructed through the engineering of a poly(ethylene glycol) diacrylate/methacrylated hyaluronic acid hydrogel; it combines rapid, sufficient extraction of ISF with excellent structural integrity. Notably, the analyte molecules in the needles can be recovered into a moist cellulose paper through spontaneous diffusion. More importantly, the paper can be functionalized with enzymatic colorimetric reagents or a plasmonic array, enabling a desired detection capacity-for example, the use of paper-based surface-enhanced Raman spectroscopy sensors leads to label-free, trace detection (sub-ppb level) of a diverse set of molecules (cefazolin, nicotine, paraquat, methylene blue). Finally, nicotine is selected as a model drug to evaluate the painless monitoring of three human volunteers. The changes in the nicotine levels can be tracked, with the levels varying significantly in response to the metabolism of drug in different volunteers. This as-designed minimally invasive sensing system should open up new opportunities for precision medicine, especially for personal healthcare monitoring.
If my hidradenitis had a voice, this is what it would say: the perspective of a young woman with Down syndrome and hidradenitis suppurativa
Authors: Alexis Sokoloff, Morgan Dykman, Gwen Sokoloff, Kishore Vellody, Kristen Holland, Jillian Rork
Journal: British Journal of Dermatology (2023)

Journal Article Corrected proof If my hidradenitis had a voice, this is what it would say: the perspective of a young woman with Down syndrome and hidradenitis suppurativa Get access Alexis Sokoloff, Alexis Sokoloff Patient and patient advocate Search for other works by this author on: Oxford Academic Google Scholar Morgan Dykman, Morgan Dykman University of Minnesota School of Medicine, Minneapolis, MN https://orcid.org/0000-0002-9261-7483 Search for other works by this author on: Oxford Academic Google Scholar Gwen Sokoloff, Gwen Sokoloff Department of Pediatrics, Division of Genetics, UMass Memorial Children's Medical Center, Worchester, MA Search for other works by this author on: Oxford Academic Google Scholar Kishore Vellody, Kishore Vellody Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA Search for other works by this author on: Oxford Academic Google Scholar Kristen Holland, Kristen Holland Department of Dermatology, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI Search for other works by this author on: Oxford Academic Google Scholar Jillian Rork Jillian Rork Department of DermatologyDepartment of Pediatrics, Dartmouth Health, Manchester, NH, USA Corresponding author: Jillian F. Rork. Email: jillian.f.rork@hitchcock.org Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, ljad108, https://doi.org/10.1093/bjd/ljad108 Published: 10 April 2023 Article history Received: 16 February 2023 Revision received: 26 March 2023 Accepted: 29 March 2023 Published: 10 April 2023 Corrected and typeset: 02 June 2023
Functional specialization of short-lived and long-lived macrophage subsets in human tonsils
Authors: Lamine Alaoui, Javiera Villar, Renaud Leclere, Simon Le Gallou, Francis Relouzat, Henri-Alexandre Michaud, Karin Tarte, Natacha Teissier, Benoît Favier, Mikaël Roussel, Elodie Segura
Journal: The Journal of Experimental Medicine (2023)

Macrophages play a central role in tissue homeostasis and host defense. However, the properties of human macrophages in non-diseased tissues remain poorly understood. Here, we characterized human tonsil macrophages and identified three subsets with distinct phenotype, transcriptome, life cycle, and function. CD36hi macrophages were related to monocytes, while CD36lo macrophages showed features of embryonic origin and CD36int macrophages had a mixed profile. scRNA-seq on non-human primate tonsils showed that monocyte recruitment did not pre-exist an immune challenge. Functionally, CD36hi macrophages were specialized for stimulating T follicular helper cells, by producing Activin A. Combining reconstruction of ligand-receptor interactions and functional assays, we identified stromal cell-derived TNF-α as an inducer of Activin A secretion. However, only CD36hi macrophages were primed for Activin A expression, via the activity of IRF1. Our results provide insight into the heterogeneity of human lymphoid organ macrophages and show that tonsil CD36hi macrophage specialization is the result of both intrinsic features and interaction with stromal cells.
Notice of Retraction and Replacement. Chaarani B, et al. Association of Video Gaming With Cognitive Performance Among Children. <i>JAMA Network Open</i>. 2022;5(10):e2235721.
Authors: Bader Chaarani, Joseph Ortigara, DeKang Yuan, Hannah Loso, Alexandra Potter, Hugh P. Garavan
Journal: JAMA Network Open (2023)

These concerns were brought to our attention by a reader, for which we are grateful.This study was conducted to examine the association between video gaming and cognition in children using data from the Adolescent Brain Cognitive Development (ABCD) study.Cognitive performance and blood oxygen level-dependent (BOLD) signal were compared in video gamers (VGs) and non-video gamers (NVGs) during response inhibition and working memory using taskbased functional magnetic resonance imaging (fMRI) among children from the ABCD study ages 9and 10 years.We collected data on demographic characteristics and mental health measures using the Child Behavior Checklist (CBCL) and attempted to control for confounding of these factors.However, the 2 groups were different in terms of sex, race and ethnicity, parental income, and some mental health and behavioral scores.We had erroneously reported this study as a case-control study, but it should have been reported as a cross-sectional study.
Ensuring Precision in Methodology for Nonfatal Firearm Injuries
Authors: Christian D. Pulcini, Eric W. Fleegler
Journal: JAMA Pediatrics (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Use of Telehealth Methods to Track Infant Neurodevelopment After In Utero SARS-CoV-2 Exposure
Authors: Sarah B. Mulkey
Journal: JAMA Network Open (2023)

Morgan R. Firestein, PhD; Lauren C. Shuffrey, PhD; Yunzhe Hu, BA; Margaret Kyle, BA; Maha Hussain, MS; Catherine Bianco, BA; Violet Hott, BA; Sabrina P. Hyman, MS; Mia Kyler, BA; Cynthia Rodriguez, BA; Melanie Tejeda Romero, BA; Helen Tzul Lopez, BA; Carmela Alcántara, PhD; Dima Amso, PhD; Judy Austin, PhD; Jennifer M. Bain, MD, PhD; Jennifer Barbosa, MA; Ashley N. Battarbee, MD, MSCR; Ann Bruno, MD; Sharon Ettinger, MA; Pam Factor-Litvak, PhD; Suzanne Gilboa, PhD; Sylvie Goldman, PhD; Cynthia Gyamfi-Bannerman, MD, MS; Panagiotis Maniatis, MS; Rachel Marsh, PhD; Tyler Morrill, MS; Mirella Mourad, MD; Rebecca Muhle, MD, PhD; Gabriella Newes-Adeyi, PhD, MPH; Kimberly G. Noble, MD, PhD; Kally C. O'Reilly, PhD; Anna A. Penn, MD, PhD; Lawrence Reichle, MPH; Ayesha Sania, ScD; Vera Semenova, PhD; Wendy G. Silver, MD, MA; Grace Smotrich, BA; Alan T. Tita, MD, PhD; Nim Tottenham, PhD; Michael Varner, MD; Martha G. Welch, MD; Noelia Zork, MD; Donna Garey, MD; William P. Fifer, PhD; Melissa S. Stockwell, MD, MPH; Catherine Monk, PhD; Fatimah Dawood, MD; Dani Dumitriu, MD, PhD
TIGIT mediates activation-induced cell death of ILC2s during chronic airway allergy
Authors: Toshiki Yamada, Megumi Tatematsu, Shunsuke Takasuga, Akane Fuchimukai, Kenki Yamagata, Shinsuke Seki, Keiji Kuba, Hideyuki Yoshida, Ichiro Taniuchi, Günter Bernhardt, Kazuko Shibuya, Akira Shibuya, Takechiyo Yamada, Takashi Ebihara
Journal: The Journal of Experimental Medicine (2023)

While group-2 innate lymphoid cells (ILC2s) are highly proliferative in allergic inflammation, the removal of overactivated ILC2s in allergic diseases has not been investigated. We previously showed that chronic airway allergy induces “exhausted-like” dysfunctional ILC2s expressing T cell immunoreceptor with Ig and ITIM domains (TIGIT). However, the physiological relevance of these cells in chronic allergy remains elusive. To precisely identify and monitor TIGIT+ ILC2s, we generated TIGIT lineage tracer mice. Chronic allergy stably induced TIGIT+ ILC2s, which were highly activated, apoptotic, and were quickly removed from sites of chronic allergy. Transcripts from coding genes were globally suppressed in the cells, possibly due to reduced chromatin accessibility. Cell death in TIGIT+ ILC2s was enhanced by interactions with CD155 expressed on macrophages, whereas genetic ablation of Tigit or blockade by anti-TIGIT antagonistic antibodies promoted ILC2 survival, thereby deteriorating chronic allergic inflammation. Our work demonstrates that TIGIT shifts the fate of ILC2s toward activation-induced cell death, which could present a new therapeutic target for chronic allergies.
Advanced translational PBPK model for transferrin receptor-mediated drug delivery to the brain
Authors: Sho Sato, Siyu Liu, Akihiko Goto, Tomoki Yoneyama, Koki Okita, Syunsuke Yamamoto, Hideki Hirabayashi, Shinji Iwasaki, Hiroyuki Kusuhara
Journal: Journal of Controlled Release (2023)

Transferrin receptor (TfR)-mediated transcytosis is an attractive pathway for delivering large-molecule therapeutics to the central nervous system across the blood-brain barrier. Despite the clinical success of some drugs conjugated with TfR-binder, the desired drug profile for efficient TfR-mediated delivery to the targeted compartment within the brain, especially considering the species-related differences, has not been fully elucidated. To provide a prospective direction in the TfR-mediated drug delivery system, we developed an advanced physiologically based pharmacokinetic (PBPK) model. The model addresses TfR-mediated trans- and intracellular disposition of anti-TfR antibodies from brain capillary blood, endothelial cells, extracellular fluid (ECF), and eventually to brain parenchymal cells (BPCs), which correspond to pharmacological target sites of interest. The PBPK model is applicable in rats, monkeys, and human TfR knock-in (hTfR-KI) mice with satisfactory prediction accuracy through model calibration using the brain and plasma PK data of anti-TfR monoclonal antibodies, including their fused protein, with diverse binding affinity to TfR (TfR-Kd). The sensitivity analysis to determine drug properties required for the optimal brain delivery revealed 1) a bell-shaped relationship between TfR-Kd and brain exposure; 2) a minimum species difference between monkeys and hTfR-KI mice in the optimal TfR-Kd range, but not with rats; 3) a low TfR-Kd range to be preferably targeted for BPCs compared with ECF; and 4) an increase in brain exposure when using the pH-sensitive antibody. This may advance model-informed drug development, improve molecular design optimization, and provide precise human dose projection of drugs leveraging TfR-mediated shuttle technology into the brain.
Health Care Access and Affordability Among US Adults Aged 18 to 64 Years With Self-reported Post–COVID-19 Condition
Authors: Michael Karpman, Stephen Zuckerman, Sarah Morriss
Journal: JAMA Network Open (2023)

Importance Many US adults report having post–COVID-19 condition (PCC), but little is known about their access to health care. Objective To estimate the association of PCC with access and affordability challenges among US adults aged 18 to 64 years. Design, Setting, and Participants This survey study used data from the Health Reform Monitoring Survey, a probability-based internet survey conducted June 17 to July 5, 2022. Participants included a nationally representative sample of 9484 US adults ages 18 to 64 years drawn from the Ipsos KnowledgePanel. Main Outcomes and Measures Self-reported PCC was defined as experiencing symptoms more than 4 weeks after first having COVID-19 that were not explained by another condition or factor. Access and affordability outcomes included having a usual place of care; forgoing care in the past 12 months because of costs, difficulty finding clinicians, or difficulty using health insurance; having problems paying family medical bills in the past 12 months; and having past-due medical debt. Results Of 19 162 panel members recruited for the survey, 9599 individuals completed the survey (completion rate, 50.1%) and 9484 respondents were included in the final analytic sample (4720 females [50.6%, weighted]; mean [SD] age, 41.0 [13.5] years). A total of 3382 respondents (36.4%; 95% CI, 34.7%-38.2%) reported ever being diagnosed with COVID-19, among whom, 833 respondents (22.5%; 95% CI, 20.9%-24.2%) reported currently having PCC. After adjustment for differences in demographic, health, and geographic characteristics, adults with PCC were more likely than 2549 adults with a COVID-19 diagnosis but no report of PCC and 6102 adults never diagnosed with COVID-19 to report unmet health care needs in the past 12 months because of the following challenges: costs (27.0%; 95% CI, 23.2%-30.7% vs 18.3%; 95% CI, 15.9%-20.7% and 17.5%; 95% CI, 15.4%-19.6%) and difficulties finding clinicians accepting new patients (16.4%; 95% CI, 14.3%-18.4% vs 10.1%; 95% CI, 8.8%-11.5% and 10.7%; 95% CI, 9.6%-11.8%), getting a timely appointment (22.0%; 95% CI, 19.3%-24.8% vs 14.4%; 95% CI, 13.2%-15.7% and 13.9%; 95% CI, 12.9%-14.8%), and getting health plan care authorization (16.6%; 95% CI, 14.6%-18.6% vs 10.8%; 95% CI, 9.6%-12.1% and 10.3%; 95% CI, 9.4%-11.2%) ( P &amp;amp;lt; .001 for all comparisons). Conclusions and Relevance This study found that adults aged 18 to 64 years with PCC were more likely than other adults to have difficulty getting and paying for health care. These findings suggest that policies aimed at improving access and affordability may focus on accelerating development of treatments and clinical guidelines, training clinicians, and addressing insurance-related administrative and cost barriers.
Examining the Hepatitis B Care Cascade Through an Equity Lens
Authors: H. Nina Kim
Journal: JAMA Network Open (2023)

Mandana Khalili, MD; Kelsey R. Leonard, MS; Marc G. Ghany, MD; Mohamed Hassan, MD; Lewis R. Roberts, MB, ChB, PhD; Richard K. Sterling, MD, MSc; Steven H. Belle, PhD, MScHyg; Anna S. Lok, MD; Hepatitis B Research Network ; Daryl T-Y Lau; Raymond T. Chung ; Adrian M Di Bisceglie; Mauricio Lisker-Melman; Harry L. A. Janssen; David K. Wong; Joshua Juan; Jordan Feld; Colina Yim; William M. Lee; Carol S. Murakam; Robert Perrillo; Son Do; Steven-Huy B. Han; Tram T. Tran; Norah A. Terrault; Stewart L. Cooper; Robert J. Fontana; Naoky Tsai; Barak Younoszai; Michael W. Fried; Jama M. Darling; Andrew Muir; Donna Evon; Robert C. Carithers; Margaret Shuhart; Kris V. Kowdley; Chia C. Wang; Velimir A. Luketic; T. Jake Liang; Jay H. Hoofnagle,; Edward Doo; Kyong-Mi Chang; Jang-June Park; Abdus Wahed; Wendy C. King; David Kleiner
Low Complexity Regions in Proteins and DNA are Poorly Correlated
Authors: Johanna M Enright, Zachery W Dickson, G Brian Golding
Journal: Molecular Biology and Evolution (2023)

Abstract Low complexity sequences (LCRs) are well known within coding as well as non-coding sequences. A low complexity region within a protein must be encoded by the underlying DNA sequence. Here, we examine the relationship between the entropy of the protein sequence and that of the DNA sequence which encodes it. We show that they are poorly correlated whether starting with a low complexity region within the protein and comparing it to the corresponding sequence in the DNA or by finding a low complexity region within coding DNA and comparing it to the corresponding sequence in the protein. We show this is the case within the proteomes of five model organisms: Homo sapiens, Saccharomyces cerevisiae, Drosophila melanogaster, Caenorhabditis elegans, and Arabidopsis thaliana. We also report a significant bias against mononucleic codons in LCR encoding sequences. By comparison with simulated proteomes, we show that highly repetitive LCRs may be explained by neutral, slippage-based evolution, but compositionally biased LCRs with cryptic repeats are not. We demonstrate that other biological biases and forces must be acting to create and maintain these LCRs. Uncovering these forces will improve our understanding of protein LCR evolution.
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!
Authors: Robert Hegarty, Anil Dhawan
Journal: Hepatology (2023)

To the editor, We read with interest the study by Younossi et al1 and the editorial by van Kleef and de Knegt2 on NAFLD/MAFLD transition and its implications. We agree with the editorial title that one size does not fit all. An attempt to further subclassify MAFLD± and NAFLD± indicates the complexity of fatty liver disease even in a relatively homogenous adult population in comparison to children in whom the differential diagnosis is wider. Furthermore, it will be impractical to subdivide children as MAFLD± or NAFLD± as not only NAFLD is already a misnomer as alcohol use is uncommon in children but also not directly relevant as liver-related mortality is overall very low. By contrast, liver steatosis in children is still a red flag for a pediatric hepatologist as a wide spectrum of inherited metabolic disorders (IMDs) need excluding particularly in young children.3 Hepatic steatosis secondary to IMD occupied 40% of a fatty liver cohort in an audit carried out in our center with important treatment implications, while MAFLD occupied 51% and neither 9%. This latter group that may be MAFLD−/NAFLD− is particularly important in children as there may be a yet undiagnosed IMD.4 We would like to further our suggestion that fatty liver disease in children comes under the heading of pediatric fatty liver disease where type 1 denotes those diagnosed with IMD; type 2, MAFLD/NAFLD; and type 3, fatty liver yet without an identifiable cause.4 This classification will help not miss serious IMD in children who may or may not be overweight or obese.
PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis
Authors: Tamara K. Moyo, Ashwin Kishtagari, Matthew T. Villaume, Brandon McMahon, Sanjay R. Mohan, Tess Stopczynski, Sheau-Chiann Chen, Run Fan, Yuankai Huo, Hyeonsoo Moon, Yucheng Tang, Cosmin A. Bejan, Merrida Childress, Ingrid Anderson, Kyle Rawling, Rhea M. Simons, Ashley Moncrief, Rebekah Caza, Laura Dugger, Aunshka Collins, Channing V. Dudley, P. Brent Ferrell, Michael Byrne, Stephen A. Strickland, Gregory D. Ayers, Bennett A. Landman, Emily F. Mason, Ruben A. Mesa, Jeanne M. Palmer, Laura C. Michaelis, Michael R. Savona
Journal: Clinical Cancer Research (2023)

Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ inhibition cooperates with ruxolitinib, a JAK1/2 inhibitor, to reduce proliferation and induce apoptosis of JAK2V617F-mutant cell lines.In a phase I dose-escalation and -expansion study, we evaluated the safety and efficacy of a selective PI3Kδ inhibitor, umbralisib, in combination with ruxolitinib in patients with MF who had a suboptimal response or lost response to ruxolitinib. Enrolled subjects were required to be on a stable dose of ruxolitinib for ≥8 weeks and continue that MTD at study enrollment. The recommended dose of umbralisib in combination with ruxolitinib was determined using a modified 3+3 dose-escalation design. Safety, pharmacokinetics, and efficacy outcomes were evaluated, and spleen size was measured with a novel automated digital atlas.Thirty-seven patients with MF (median age, 67 years) with prior exposure to ruxolitinib were enrolled. A total of 2 patients treated with 800 mg umbralisib experienced reversible grade 3 asymptomatic pancreatic enzyme elevation, but no dose-limiting toxicities were seen at lower umbralisib doses. Two patients (5%) achieved a durable complete response, and 12 patients (32%) met the International Working Group-Myeloproliferative Neoplasms Research and Treatment response criteria of clinical improvement. With a median follow-up of 50.3 months for censored patients, overall survival was greater than 70% after 3 years of follow-up.Adding umbralisib to ruxolitinib in patients was well tolerated and may resensitize patients with MF to ruxolitinib without unacceptable rates of adverse events seen with earlier generation PI3Kδ inhibitors. Randomized trials testing umbralisib in the treatment of MF should be pursued.
Ensuring Precision in Methodology for Nonfatal Firearm Injuries—Reply
Authors: Stephanie E. Iantorno
Journal: JAMA Pediatrics (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal